20.38
-1.36%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Giant Biogene Holding Co
Its shares trade on HKEX under the ticker 2367.HK. It has been listed since 4 November 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥6.43bn and net income of CN¥2.23bn. At that date it held total assets of CN¥12.63bn and shareholders' equity of CN¥11.55bn.
Giant Biogene Holding Co. Ltd. engages in providing bioactive material-based beauty and health products. The company is headquartered in Xi'An, Shaanxi. The company went IPO on 2022-11-04. The firm is principally engaged the research, development, manufacture and sale of bioactive material-based beauty and health products through its subsidiaries. The firm's main products include functional skincare products and medical dressings, and they are produced with recombinant collagen as the key bioactive ingredient. The firm also develops and manufactures rare ginsenosides technology-based functional foods. The firm mainly conducts its businesses within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 4 Nov 2022
- Employees
- 1,023
- Website
- xajuzi.com ↗
Leadership
Pay as last reported
- Mr. Jianya YanExecutive Chairman of the Board, Chief Executive Officer, since 2021CN¥11.0m
- Ms. Huijuan ZhangChief Financial Officer, Executive Director, since 2022CN¥3.4m
- Ms. Juan FangSenior Vice President, Executive Director, since 2021CN¥4.3m
- Ms. Juan YeSenior Vice President, Executive Director, since 2021CN¥4.1m
- Mr. Zhiguang DuanSenior Vice President
- Ms. Yajuan YanSenior Vice President
- Ms. Yubo YanExecutive Director, Joint Company Secretary and Board Secretary, Chief Product Officer, since 2022CN¥362,000
- Ms. Wing Yan YuenJoint Company Secretary
- Mr. Jin HuangNon-Executive Independent DirectorCN¥109,000
- Mr. Wenhua ShanNon-Executive Independent DirectorCN¥109,000
- Ms. Sze Wing WongNon-Executive Independent DirectorCN¥183,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 53
- Social
- 38
- Governance
- 59
- Direct emissions (scope 1)
- 1,505.67 t
- Energy emissions (scope 2)
- 4,939.74 t
- Women in the workforce
- 59.53608%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Xi'an, China, with 1,023 employees.
- Operates in the Consumer Staples sector with a focus on bioactive material-based products.
- Offers functional skincare products and medical dressings using recombinant collagen.
Weaknesses
- Primarily operates within the domestic market, limiting international expansion.
- Relies on a single key bioactive ingredient, recombinant collagen, for main products.
- IPO occurred in 2022, indicating a relatively new public company with limited market history.
Opportunities
- Potential growth in the domestic market for bioactive material-based beauty and health products.
- Expansion into international markets for functional skincare and medical dressings.
- Development of rare ginsenosides technology-based functional foods could open new revenue streams.
Threats
- Dependence on recombinant collagen as a key ingredient may pose supply chain risks.
- Competition in the domestic market for bioactive material-based products.
- Regulatory changes affecting the production and sale of health and beauty products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.